A Phase II Study of Patients with Newly Diagnosed Primary Central Nervous System Lymphoma Treated with Methotrexate/BBBD, and Adding Rituximab (an anti CD-20 Antibody) and Carboplatin, to the Treatment Regimen
The purpose of this study is to evaluate the safety and tolerability of chemotherapy delivered in conjunction with a special technique called blood-brain barrier disruption (BBBD) in patients with primary central nervous system lymphoma (PCNSL) who have not undergone prior cranial or spinal radiotherapy. Participants of this study will be hospitalized for approximately three days every four weeks, to receive chemotherapy. The drug rituximab will be administered intra-venously, the evening prior to carboplatin (intra-arterial) and methotrexate (intra-arterial) chemotherapy. The two chemotherapy drugs will be administered in conjunction with BBBD. If the patient has lymphoma in the eye, chemotherapy will be given into the eye(s) as well. Participants will receive the drug sodium thiosulfate (intra-venous) four and eight hours after carboplatin, in an effort to reduce side effects associated with this chemotherapy regimen. The treatment may continue for up to 12 months in the absence of disease progression or unacceptable side effects.
Brain & Nervous System
Primary central nervous system lymphoma (PCNSL)
No prior cranial or spinal radiotherapy
No systemic lymphoma
No more than 90 days since diagnosis of PCNSL
Must be HIV negative
Must be Hepatitis B and Hepatitis C negative
Age 18 to 75 years
18 - 75
Healthy Volunteers Needed
Duration of Participation
The treatment may continue for up to 12 months in the absence of disease progression or unacceptable side effects.
Edward A Neuwelt, MD 503-494-5626 email@example.com
National Cancer Institute